UNSPSC 51321802: Aluminium clofibrate

This classification denotes an anti-lipidemic agent with the molecular formula 2C10H10ClO3.Al.HO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 56203T2K2X, chemically known as propanoic acid, 2-(4-chlorophenoxy)-2-methyl-, aluminum complex but generally known as aluminium clofibrate, which bears US NIH Compound Identifier 16683028. European Medicines Agency schedules Aluminium clofibrate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB12820MIG.

UNSPSC 51321802 Aluminium clofibrate (Commodity) covers pharmaceutical products supplied to state and local government entities, though recent solicitations under this code show activity focused broadly on emergency-response medications, prescription-benefit-program support, and multi-source generic pharmaceuticals rather than aluminium clofibrate specifically. State and local governments soliciting under this code are purchasing sealed-bid supplies of advanced life support medications for emergency medical services, exploring direct-to-manufacturer prescription programs to optimize pharmacy benefit delivery, and establishing cooperative purchasing agreements for generic and over-the-counter pharmaceutical products across multiple jurisdictions. Issuing bodies include municipal fire departments, state health and human services commissions, and multistate cooperative purchasing alliances administering contracts on behalf of participating government facilities.

The code sees recent activity across Florida, Texas, and Minnesota, with the most visible concentration in cooperative multistate agreements. The City of Tampa's Purchasing Department issued an IFB (Solicitation 26P00188) in April 2026 for Advanced Life Support Medications to supply Tampa Fire Rescue with epinephrine, labetalol, adenosine, and diltiazem in quantities ranging from 330 to 1,810 units, with a contract value of $40,000.00 and a response deadline of April 8, 2026; the solicitation included a Small Local Business Enterprise sheltered-market 5 percent bid discount. The Minnesota Department of Administration's Office of State Procurement, administering the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), issued an RFP (S1070000015802) closing March 26, 2026, for generic multi-source pharmaceuticals and OTC products to be distributed across state and local facilities in Minnesota and Oregon, with awards effective July 1, 2026. The Texas Health and Human Services Commission issued a Request for Information (HHS0017013) in April 2026 to gather vendor capabilities for implementing a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, signaling preliminary procurement planning for future formal solicitations.